Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.37 |
| ▸ | PREP | P48147 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7850221 | 0.87 | CHRM2 (0.58) | CHRM2CHRM1CHRM3HSD11B1HRH3 | |
| SCHEMBL18390342 | 0.87 | CHRM2 (0.54) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL5243293 | 0.82 | CHRM2 (0.51) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL11993192 | 0.82 | CHRM2 (0.51) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL8305574 | 0.82 | CHRM2 (0.64) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL11993160 | 0.80 | CHRM2 (0.50) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL24726807 | 0.79 | CHRM2 (0.44) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL911596 | 0.79 | CHRM2 (0.56) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL25343472 | 0.78 | CHRM2 (0.51) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL17483515 | 0.78 | CHRM2 (0.55) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| WO-2023099624-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023099612-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | CHRM2 903/4885CHRM1 1100/4885CHRM3 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.